Drug Trial Radar · NCT06767774
Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Apr 25, 2025
Primary completion
Aug 31, 2029
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Korea University Anam HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Daewon Pharmaceutical Co., Ltd.; Samjin Pharmaceutical Co., Ltd.
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The AVOID-DM trial is a multicenter, prospective, randomized study comparing the risk of new-onset diabetes mellitus (DM) between two cholesterol-lowering strategies in patients with prediabetes and established atherosclerotic cardiovascular disease (ASCVD). The study evaluates pitavastatin plus ezetimibe combination therapy versus high-intensity statin monotherapy (rosuvastatin 20 mg). Enrolling 2,000 non-diabetic participants with ASCVD, subjects are randomized 1:1 into the two treatment arms. The primary outcome is the incidence of new-onset DM over a follow-up period of up to 36 months. Secondary outcomes include cardiovascular events, changes in LDL cholesterol, fasting glucose, HbA1c, and insulin resistance. This trial hypothesizes that the combination therapy will achieve LDL targets with a lower risk of new-onset DM compared to high-intensity statin monotherapy.
Conditions
- ASCVD
- Diabetes
- Statin
Interventions
Combination therapyDrug
* pitavastatin 4mg * ezetimibe 10mg
High intensity statin monotherapyDrug
rosuvastatin 20mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- new-onset diabetes mellitus meeting diagnostic criteria for conventional diabetes during the treatment periodTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.